Trial Profile
The protective effect for renal function of Aliskiren in hypertensive CKD patients with proteinuria
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Calcium channel antagonists; Candesartan cilexetil; Losartan; Olmesartan medoxomil; Telmisartan; Valsartan
- Indications Hypertension
- Focus Pharmacodynamics
- 18 Jun 2013 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
- 14 Dec 2012 Planned end date changed from 1 Dec 2012 to 31 Dec 2013 as reported by University Hospital Medical Information Network - Japan.
- 01 Sep 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan